Raymond James Upgrades Inflarx NV (IFRX) to Strong Buy May 13, 2026 07:16AM
InflaRx completes $150 million share offering at $2.00 per share May 8, 2026 08:17AM
InflaRx prices $150 million stock offering at $2 per share May 6, 2026 08:31AM
InflaRx advances izicopan development for kidney diseases May 6, 2026 08:26AM
InflaRx shows lower reactive metabolite formation for izicopan vs avacopan May 4, 2026 07:31AM


Apr 21, 2026 06:51AM Guggenheim Reiterates Buy Rating on Inflarx NV (IFRX)
Mar 30, 2026 07:30AM InflaRx presents vilobelimab data for pyoderma gangrenosum at AAD meeting
Mar 20, 2026 04:14PM Inflarx NV (IFRX) PT Raised to $7 at Raymond James
Mar 20, 2026 06:59AM Inflarx NV (IFRX) PT Lowered to $14 at Guggenheim
Jan 8, 2026 08:11AM InflaRx cuts 30% of workforce to focus on izicopan development
Dec 31, 2025 06:37AM Raymond James on Inflarx NV (IFRX): 'analyses of the unblinded Phase 3 dataset for vilobelimab...suggests evidence of a positive trend'
Dec 11, 2025 07:32AM InflaRx receives international nonproprietary name izicopan for INF904
Dec 3, 2025 06:41AM Leerink Partners Downgrades Inflarx NV (IFRX) to Market Perform
Nov 11, 2025 04:26AM Inflarx NV (IFRX) PT Raised to $9 at Raymond James
Sep 2, 2025 06:19AM H.C. Wainwright Assumes Inflarx NV (IFRX) at Buy
Jul 11, 2025 04:15PM InflaRx receives NASDAQ deficiency notice for minimum bid price
May 29, 2025 03:46AM Raymond James Downgrades Inflarx NV (IFRX) to Outperform
May 28, 2025 10:35AM Guggenheim Reiterates Buy Rating on Inflarx NV (IFRX)
May 28, 2025 04:55AM InflaRx N.V. (IFRX) Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
May 13, 2025 04:37PM Raymond James Reiterates Strong Buy Rating on Inflarx NV (IFRX), PT $13
Apr 29, 2025 06:32AM Cantor Fitzgerald Starts Inflarx NV (IFRX) at Overweight
Mar 26, 2025 06:57AM Inflarx NV (IFRX) PT Raised to $10 at Guggenheim
Feb 13, 2025 04:01PM InflaRx (IFRX) Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
Jan 16, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Inflarx NV (IFRX)
Jan 15, 2025 12:30PM InflaRx N.V. (IFRX) Receives European Commission Approval for GOHIBIC for the Treatment of SARS-CoV-2-Induced ARDS
Dec 23, 2024 07:11AM H.C. Wainwright Reiterates Buy Rating on Inflarx NV (IFRX)
Nov 19, 2024 08:07AM Lucid Capital Markets Starts Inflarx NV (IFRX) at Buy
Nov 15, 2024 07:52AM InflaRx (IFRX) Receives Positive CHMP Opinion for GOHIBIC for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Sep 26, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Inflarx NV (IFRX)
Sep 25, 2024 07:31AM InflaRx (IFRX) Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
Sep 3, 2024 07:30AM InflaRx N.V. (IFRX) Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
Aug 8, 2024 07:39AM InflaRx N.V. (IFRX) Misses Q2 EPS by 4c
Jun 24, 2024 08:04AM InflaRx N.V.'s (IFRX) GOHIBIC Selected for First BARDA-Sponsored Trial